ATANIS Biotech AG, a Bern-based company specializing in functional allergy diagnosis, completed an oversubscribed capital raise. The funds will be used to accelerate marketing efforts of FAST-PASE, a safe, functional ex vivo allergy assay.

阿塔尼斯生物技术公司是一家位于伯尔尼的专门从事功能性过敏诊断的公司，完成了超额认购的融资。这些资金将用于加速FAST-PASE的营销工作，FAST-PASE是一种安全，功能强大的离体过敏检测方法。

Worldwide the prevalence of allergies is continuously rising. With one third of the global population affected by allergic conditions, it almost reaches epidemic levels. However, current diagnostic procedures for allergy rely on risky, uncomfortable, cumbersome, and outdated functional in vivo allergen exposures.

在世界范围内，过敏的患病率不断上升。由于全球三分之一的人口受到过敏性疾病的影响，它几乎达到了流行水平。然而，目前的过敏诊断程序依赖于风险，不舒服，麻烦和过时的功能性体内过敏原暴露。

ATANIS has developed a novel, functional ex vivo mast cell activation test, named FAST-PASE. The assay uses shelf-stable patient serum, which enables scalability. In recent diagnostic accuracy studies FAST-PASE has outperformed other established clinical methods and procedures to identify allergies..

ATANIS开发了一种新型的功能性离体肥大细胞活化测试，称为FAST-PASE。该测定法使用货架稳定的患者血清，可实现可扩展性。在最近的诊断准确性研究中，FAST-PASE在识别过敏方面优于其他既定的临床方法和程序。。

In addition, FAST-PASE has been optimized for high throughput measurement. Using a fluorescent cellular barcoding method, ATANIS can significantly increase sample throughput. This is an ideal way to screen large patient cohorts (e.g. clinical trials) or identify lead molecules from a library of potential candidates..

此外，FAST-PASE已针对高通量测量进行了优化。使用荧光细胞条形码方法，ATANIS可以显着提高样品吞吐量。这是筛选大型患者队列（例如临床试验）或从潜在候选人库中识别铅分子的理想方法。。

ATANIS Biotech is pursuing regulatory approval of its proprietary mast cell activation test for use in a clinical setting in the US, EU, and Switzerland. Discussions with the FDA are underway to bring FAST-PASE to the US market as fast as possible.

ATANIS Biotech正在寻求其专有肥大细胞活化测试的监管批准，以用于美国，欧盟和瑞士的临床环境。正在与FDA讨论尽快将FAST-PASE引入美国市场。

An oversubscribed funding round enables ATANIS to accelerate the progress of FAST-PASE. The round was led by Spectrum Moonshot Fund, an investment vehicle backed by a prominent Swiss family with a strong focus on high-growth technology startups. Additional funding was provided by seasoned investors in the allergy sector, along with contributions from existing backers..

超额认购的资金回合使ATANIS能够加速FAST-PASE的进展。这一轮由Spectrum Moonshot Fund牵头，该基金是一家由瑞士著名家族支持的投资工具，专注于高成长性科技初创公司。过敏领域经验丰富的投资者提供了额外的资金，以及现有支持者的贡献。。

ATANIS Biotech also generates revenue by serving over 20 institutional clients from pharma, biotech, and agri-food industry with different needs ranging from pre-clinical compound screening to efficacy assessment of selected drug candidates.

ATANIS Biotech还通过为来自制药，生物技术和农业食品行业的20多家机构客户提供服务来产生收入，这些客户的需求从临床前化合物筛选到选定候选药物的功效评估不等。

“I am delighted to have completed this oversubscribed capital increase in record time” said Pr. Dr. Jean- Pierre Kinet, CEO of ATANIS Biotech. “This will enable us to accelerate our marketing efforts of FASTPASE in the United States and Europe, and help us to more rapidly address the urgent need for a safe, functional ex vivo allergy assay for patients”.

ATANIS Biotech首席执行官Jean-PierreKinet博士说：“我很高兴在创纪录的时间内完成了超额认购的增资。”。“这将使我们能够加速FASTPASE在美国和欧洲的营销工作，并帮助我们更快地满足对患者安全，功能性离体过敏测定的迫切需求”。

As part of this capital raise, Mr. Jascha Forster has joined the board of the company, where he will contribute his expertise in financing and management of rapid growth enterprises. “I look forward to working with ATANIS’ leadership team and better serve allergy patients”, declared Mr. Forster.

作为此次融资的一部分，Jascha Forster先生加入了公司董事会，他将在董事会中贡献自己在快速增长企业融资和管理方面的专业知识。福斯特先生宣称：“我期待着与阿塔尼斯的领导团队合作，更好地为过敏患者服务。”。

(Press release / SK)

（新闻稿/SK）

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送